Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

The UWMDI is the first of its kind in the Pacific Northwest, integrating state-of-the-art research programs with superb care for patients with diabetes, obesity and their complications ...

Scientists at the University of Virginia have uncovered how different exercise intensifies the impact of the hunger hormone ...

Hi there! If you’re here, chances are you’re on a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, and you’re looking ...

In December 2024, the Centers for Medicare & Medicaid Services (CMS) formally approved a new quality measure developed by the ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

Whoopi displayed her slimmed-down physique in a beautiful black silk wrap dress that fell just above her ankles and cinched in her waist with a belt with gold loops. The actress looked extremely ...

Former BBC Radio 4 presenter Dame Jenni Murray has bravely opened up on the lasting impact her mother's obsession with weight ...